This study is a prospective multicenter single-arm phase II clinical trial. Rectal cancer patients with cT3 stage will receive neoadjuvant chemoradiotherapy, and be evaluated the response of the tumor in 6 to 10 weeks after completion of neoadjuvant chemoradiotherapy. For those who have good response (ycT0-1) will underwent transanal local excision under the patients' agree.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age: more than 20 years
biopsy-proven adenocarcinoma of the rectum
clinical staging, cT3NxM0
Rectal cancer located 8 cm from the anal verge
Restaging in 6-10 weeks after completion of neoadjuvant chemoradiotherapy, ycT0-1N0M0
ECOG performance status 2 or less
You may not be if
Synchronous colon cancer or other malignancy
Obstructing rectal cancer
Pregnant or breast-feeding
Receiving any other study agents
History of prior colorectal cancer or inflammatory bowel disease
Hereditary colorectal cancer (FAP, HNPCC)
Clareo Health | Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy
